Shore Capital Reaffirms “Buy” Rating for Verona Pharma (LON:VRP)

Shore Capital restated their buy rating on shares of Verona Pharma (LON:VRP) in a research report released on Tuesday, June 4th, ThisIsMoney.Co.Uk reports.

VRP remained flat at $GBX 58.50 ($0.76) during midday trading on Tuesday. 4,031 shares of the company’s stock were exchanged, compared to its average volume of 49,797. The company has a market cap of $61.65 million and a P/E ratio of -6.09. The company has a quick ratio of 10.02, a current ratio of 10.43 and a debt-to-equity ratio of 0.42. Verona Pharma has a twelve month low of GBX 48 ($0.63) and a twelve month high of GBX 154 ($2.01). The firm has a 50-day moving average price of GBX 58.81.

In other Verona Pharma news, insider Piers Morgan acquired 33,802 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were acquired at an average price of GBX 59 ($0.77) per share, for a total transaction of £19,943.18 ($26,059.30).

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.

Further Reading: Why is the ex-dividend date different from the record date?

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply